文献速递免疫规划传染病防控与疫情报告

四价裂解病毒体灭活流感疫苗在9-59岁健康人群中批间一致性、免疫原性与安全性的随机双盲对照IV期临床试验

Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
PubMed 文献 · Vaccine · 2024-08-06

在中国贵州省9-59岁健康人群中开展随机双盲IV期试验,1260名受试者按1:1:1接种三个生产批次的四价灭活流感疫苗。接种后28天各批次针对全部4株病毒的HI抗体GMT比值95%CI均落在(0.67, 1.5)等效区间内,血清阳转率和血清保护率均达到CBER标准,三个批次间不良反应发生率相似,未发现安全性问题。

要点

  • 三个生产批次IIV4的免疫原性批间一致,GMT比值95%CI均落在(0.67, 1.5)内。
  • 各批次全部4株病毒的SCR和SPR均达到CBER标准(SCR 95%CI下限≥40%,SPR≥70%)。
  • 三个批次不良反应发生率相似,91.9%为轻或中度,11例严重不良事件均判定与接种无关。

核心结论

  • 三个生产批次的四价灭活流感疫苗免疫原性一致,对全部4株病毒均可诱导满意的免疫应答,未发现安全性问题。

研究设计与样本

  • 在贵州省9-59岁健康儿童、青少年和成人中开展随机、双盲、对照IV期临床试验。
  • 1260名合格受试者按1:1:1随机分为三组,各接种一个生产批次的单剂IIV4。
  • 接种前和接种后28天采集血清进行血凝抑制(HI)抗体检测,安全性数据收集至接种后28天。
  • 主要目的是通过接种后28天HI抗体几何平均滴度(GMT)评价免疫应答的批间一致性。

主要发现

  • 2022年11月27日至2022年12月18日共入组1260名合格受试者,各组人口学特征相似。
  • 接种后各组免疫应答相当,全部4株病毒的GMT比值95%CI均落在(0.67, 1.5)等效标准内。
  • 各批次全部4株病毒的血清阳转率(SCR)和血清保护率(SPR)均达到美国生物制品评价与研究中心(CBER)标准(SCR的95%CI下限≥40%,SPR≥70%)。
  • 三个批次间征集性和非征集性不良反应发生率相似,其中91.9%为轻或中度。
  • 研究期间共报告11例严重不良事件,均判定与接种无关。

关键数值与推荐

  • 批间一致性等效标准:GMT比值95%CI落在(0.67, 1.5)内。
  • CBER标准:SCR的95%CI下限≥40%,SPR≥70%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study was to assess the lot-to-lot consistency, immunogenicity and safety of three manufacturing lots of a quadrivalent inactivated influenza vaccine (IIV4). METHODS: A randomized, double-blind, phase IV clinical trial was conducted in healthy children, adolescents and adults aged 9-59 years in Guizhou Province, China. Eligible participants were enrolled and randomized into three groups in a ratio of 1:1:1 to receive a single dose of one of three manufacturing lots of IIV4. Serum samples were collected before and 28 days after vaccination for hemagglutination inhibition (HI) antibody testing. Safety data were collected for up to 28 days after vaccination. The primary objective was to evaluate the lot-to-lot consistency of immune response as assessed by the geometric mean titer (GMT) of HI antibody at 28 days after vaccination. RESULTS: Between November 27, 2022 and December 18, 2022, 1260 eligible participants were enrolled, with similar participant demographics among groups. Immune responses after vaccination were comparable across groups, with the 95% confidence intervals (CIs) of GMT ratios for all 4 strains falling into the equivalence criterion of (0.67, 1.5). The seroconversion rates (SCRs) and seroprotection rates (SPRs) met the US Center or Biologics Evaluation and Research (CBER) criteria for all strains for each lot (lower limit of 95% CI of SCR ≥ 40% and SPR ≥ 70%). The incidences of solicited and unsolicited adverse reactions were similar among three groups, most of which (91.9%) were mild or moderate in severity. A total of 11 serious adverse events were reported during the study, and all were considered unrelated to vaccination. CONCLUSION: The three manufacturing lots of IIV4 demonstrated consistent immunogenicity. IIV4 can elicit satisfactory immune responses for all four strains and no safety concerns were identified. CLINICAL TRIAL REGISTRATION: Identifier No. NCT05512494.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gao Y, Yang X, Li X, et al. Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial. Vaccine. 2024. PMID: 39116486. doi:10.1016/j.vaccine.2024.126182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。